Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.

ABSTRACT: The introduction of directly acting antiviral agents (DAAs) has produced significant improvements in the ability to cure chronic hepatitis C infection. However, with over 2% of the world's population infected with HCV, complications arising from the development of cirrhosis of the liver, chronic hepatitis C infection remains the leading indication for liver transplantation. Several modelling studies have indicated that DAAs alone will not be sufficient to eliminate HCV, but if combined with an effective vaccine this regimen would provide a significant advance towards achieving this critical World Health Organisation goal. We have previously generated a genotype 1a, 1b, 2a, 3a HCV virus like particle (VLP) quadrivalent vaccine. The HCV VLPs contain the core and envelope proteins (E1 and E2)

SUBMITTER: Christiansen D 

PROVIDER: S-EPMC6592879 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature